WO2014108497A3 - Vaccine composition comprising e. coli positive for f18 fimbria and/or f4 fimbria - Google Patents

Vaccine composition comprising e. coli positive for f18 fimbria and/or f4 fimbria Download PDF

Info

Publication number
WO2014108497A3
WO2014108497A3 PCT/EP2014/050368 EP2014050368W WO2014108497A3 WO 2014108497 A3 WO2014108497 A3 WO 2014108497A3 EP 2014050368 W EP2014050368 W EP 2014050368W WO 2014108497 A3 WO2014108497 A3 WO 2014108497A3
Authority
WO
WIPO (PCT)
Prior art keywords
fimbria
vaccine composition
coli positive
coli
positive
Prior art date
Application number
PCT/EP2014/050368
Other languages
French (fr)
Other versions
WO2014108497A2 (en
Inventor
Flemming Velin
Original Assignee
Velin-Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velin-Pharma A/S filed Critical Velin-Pharma A/S
Priority to EP14700580.5A priority Critical patent/EP2943220A2/en
Publication of WO2014108497A2 publication Critical patent/WO2014108497A2/en
Publication of WO2014108497A3 publication Critical patent/WO2014108497A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the screening and selection for specific wild type E. coli bacteria to be used in vaccines against Edema Disease (ED) and/or Post Weaning Diarrhea (PWD) in piglets.
PCT/EP2014/050368 2013-01-10 2014-01-10 Vaccine WO2014108497A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14700580.5A EP2943220A2 (en) 2013-01-10 2014-01-10 Vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201370011 2013-01-10
DKPA201370011 2013-01-10

Publications (2)

Publication Number Publication Date
WO2014108497A2 WO2014108497A2 (en) 2014-07-17
WO2014108497A3 true WO2014108497A3 (en) 2014-09-04

Family

ID=49989689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/050368 WO2014108497A2 (en) 2013-01-10 2014-01-10 Vaccine

Country Status (2)

Country Link
EP (1) EP2943220A2 (en)
WO (1) WO2014108497A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10688129B2 (en) 2013-11-26 2020-06-23 Central Biomedia, Inc. Method of producing a designer blood product, method of using a designer blood product, and diet for selectively enhancing blood profile
CN109468256B (en) * 2018-11-27 2020-08-07 扬州大学 Probiotic clone strain integrating four-copy F18 pilus operon gene and double-copy F4 pilus operon gene and construction method
CN109504643B (en) * 2018-11-27 2022-06-10 扬州大学 Probiotic clone strain integrating four-copy functional F18 pilus operon gene, construction method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ110096A3 (en) * 1996-04-17 1997-08-13 Vyzk Ustav Vet Lekarstvi Escherichia coli micro-organism strain
WO2000058476A1 (en) * 1999-03-31 2000-10-05 Mta Állatorvos-Tudományi K.I. A strain suitable for producing a live, orally applicable escherichia coli vaccine for the prevention of postweaning diarrhoea in pigs and the procedure suitable for producing that strain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ110096A3 (en) * 1996-04-17 1997-08-13 Vyzk Ustav Vet Lekarstvi Escherichia coli micro-organism strain
WO2000058476A1 (en) * 1999-03-31 2000-10-05 Mta Állatorvos-Tudományi K.I. A strain suitable for producing a live, orally applicable escherichia coli vaccine for the prevention of postweaning diarrhoea in pigs and the procedure suitable for producing that strain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERTSCHINGER H U ET AL: "ACTIVE ORAL IMMUNIZATION OF SUCKLING PIGLETS TO PREVENT COLONIZATION AFTER WEANING BY ENTEROTOXIGENIC ESCHERICHIA COLI WITHFIMBRIAE F18", VETERINARY MICROBIOLOGY, ELSEVIER BV, NL, vol. 71, no. 3/04, 1 February 2000 (2000-02-01), pages 255 - 267, XP000923246, ISSN: 0378-1135, DOI: 10.1016/S0378-1135(99)00166-2 *
BOZIC FRANE; BANOVIC FRANC; SURAN JELENA; CRNIC ANDREJA PREVENDAR: "Adjuvant activity of levamisole for experimental F18ac+ Escherichiacoli oral vaccine against porcine post-weaning colibacillosis", VETERINARSKI ARHIV : CASOPIS VETERINARSKOG FAKULTETA SVEUCILISTA U ZAGREBU, vol. 81, no. 2, 1 January 2011 (2011-01-01), HR, pages 199 - 209, XP055105919, ISSN: 0372-5480 *
See also references of EP2943220A2 *

Also Published As

Publication number Publication date
EP2943220A2 (en) 2015-11-18
WO2014108497A2 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
WO2017070616A3 (en) Sexually transmitted disease vaccines
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2016094810A3 (en) Microencapsulated cannabinoid compositions
SG10201900041VA (en) Meningococcus vaccines
MX2015012379A (en) Novel lactobacillus strains and the uses thereof.
GB2532302B (en) Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms.
MX2016006189A (en) Extract of algae for use as an immunomodulatory agent.
IL261777A (en) Palatable compositions including sodium phenylbutyrate and uses thereof
MX2018005462A (en) Chimeric RSV, Immunogenic Compositions, and Methods of Use.
WO2014108497A3 (en) Vaccine composition comprising e. coli positive for f18 fimbria and/or f4 fimbria
WO2016141320A3 (en) Non-neuroinvasive viruses and uses thereof
MX2016009464A (en) Compositions for use in the treatment of allergic conditions.
WO2014160985A3 (en) Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
WO2014133811A3 (en) Compounds from invasive salvinias and methods of using the same
MX2018014532A (en) A method of reducing egg contamination.
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants
FR3024820B1 (en) COMPOSITION COMPRISING ARTHROPOD EGGS
BR112015029862A2 (en) flavor modification ingredient
IN2014MU00284A (en)
Brooks Speech to the Young: Speech to the Progress-toward (among Them Nora and Henry III).
WO2016077580A3 (en) Compositions and methods for treating melanoma
WO2014189942A3 (en) Compositions and methods for diagnosing, preventing, and treating salmonella typhi and salmonella paratyphi infection
WO2015164336A3 (en) Biomass extracts and methods thereof
HD SUPER-EGO
Hoshyaripour Volcanic ash particles hold clues to their history and effects

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14700580

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2014700580

Country of ref document: EP